Expanding Applications in Neurodegenerative Diseases

Toru Yamashita,Koji Abe
DOI: https://doi.org/10.3390/ijms25052945
IF: 5.6
2024-03-04
International Journal of Molecular Sciences
Abstract:The brain is susceptible to oxidative stress, which is associated with various neurological diseases. Edaravone (MCI-186, 3-methyl-1 pheny-2-pyrazolin-5-one), a free radical scavenger, has promising effects by quenching hydroxyl radicals (∙OH) and inhibiting both ∙OH-dependent and ∙OH-independent lipid peroxidation. Edaravone was initially developed in Japan as a neuroprotective agent for acute cerebral infarction and was later applied clinically to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. There is accumulating evidence for the therapeutic effects of edaravone in a wide range of diseases related to oxidative stress, including ischemic stroke, ALS, Alzheimer's disease, and placental ischemia. These neuroprotective effects have expanded the potential applications of edaravone. Data from experimental animal models support its safety for long-term use, implying broader applications in various neurodegenerative diseases. In this review, we explain the unique characteristics of edaravone, summarize recent findings for specific diseases, and discuss its prospects for future therapeutic applications.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The paper attempts to address the therapeutic effects and potential applications of the antioxidant Edaravone in neurodegenerative diseases. Specifically, the paper focuses on the following aspects: 1. **Basic properties and mechanisms of Edaravone**: Edaravone is a free radical scavenger that can quench hydroxyl radicals (·OH) and inhibit lipid peroxidation. Its unique water and lipid solubility allows it to function in different environments. 2. **Neuroprotective effects in acute stroke**: Through animal experiments and clinical trials, the study investigates the therapeutic effects of Edaravone on acute stroke, including reducing brain edema, shrinking infarct size, and improving neurological deficits. 3. **Therapeutic effects on Amyotrophic Lateral Sclerosis (ALS)**: Edaravone slows down the decline in motor function in ALS mouse models by inhibiting downstream free radicals and related inflammatory responses, and has shown effects in slowing ALS progression in clinical trials. 4. **Therapeutic potential for Alzheimer's Disease (AD)**: In the context of chronic cerebral hypoperfusion (CCH), Edaravone can improve cognitive and motor function deficits in AD mouse models, reduce the accumulation of β-amyloid (Aβ) and phosphorylated Tau protein, and alleviate neuronal loss and oxidative stress. 5. **Therapeutic effects on placental ischemia**: Edaravone significantly increases fetal survival rate, length, and weight in mouse models of placental ischemia, and improves the tissue structure and function of the maternal kidneys. In summary, this paper aims to comprehensively summarize the therapeutic effects and potential mechanisms of Edaravone in various neurodegenerative diseases and explore its possible future applications.